Saturday, August 1, 2026 5:13 AM ET

CATALYST News

Earnings Insight

Earnings Calendar

Date Time Symbol company_name Period Metric Estimate Actual Surprise YrAgo Growth sector_industry
07/31/2026 BMO ABBV AbbVie Q2 2026 EPS 3.70 2.97
07/31/2026 BMO ABBV AbbVie Q2 2026 REV 16.75 B 0.00 15.42 B 0.00
07/31/2026 BMO AN AutoNation Q2 2026 EPS 5.49 5.46
07/31/2026 BMO AN AutoNation Q2 2026 REV 7.02 B 6.97 B
07/31/2026 BMO ARES Ares Management Q2 2026 EPS 1.31 1.03
07/31/2026 BMO ARES Ares Management Q2 2026 REV 1.23 B 0.00 900.62 M 0.00
07/31/2026 BMO AU Anglogold Ashanti Q2 2026 EPS 2.17 1.25
07/31/2026 BMO AU Anglogold Ashanti Q2 2026 REV 3.19 B 2.41 B
07/31/2026 BMO BBUC Brookfield Business Q2 2026 EPS 0.46 0.12
07/31/2026 BMO BBUC Brookfield Business Q2 2026 REV 0.00 6.70 B 0.00

Pre-Market Insights

Pre-Market Movers

Date Time Symbol Company Name Last Updated PrevClose Price Change Percent stockprice52wklow stockprice52wkhigh 52Wk Range company_sector company_industry Sector / Industry dailyvolume marketcap news_link Catalyst News
07/31/2026 07:04 PM CLDI Calidi Biotherapeutics, Inc. 31-Jul 09:20 1.67 1.78 1.69 1,877.78 1.48 117.12 $1.48 ~ $117.12 Healthcare Biotechnology 387.25 770.00
07/31/2026 07:05 PM WETO Wetour Robotics Limited 31-Jul 09:20 0.09 0.11 0.08 266.67 0.03 2.51 $0.03 ~ $2.51 Technology Software - Application 1,444.16 7.12
07/31/2026 07:05 PM MGRX Mangoceuticals, Inc. 31-Jul 09:20 0.56 0.67 0.38 131.03 0.16 2.75 $0.16 ~ $2.75 Healthcare Health Information Services 504.56 5.65
07/31/2026 07:05 PM REPL Replimune Group, Inc. 31-Jul 09:20 11.20 12.35 6.94 128.28 1.50 12.50 $1.50 ~ $12.50 Healthcare Biotechnology 33.24 940.40 Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote
Benzinga | 2026-07-31 10:09:17
Replimune surges after FDA advisers back skin cancer drug
Reuters | 2026-07-31 05:40:30
A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works
WSJ | 2026-07-30 17:27:00
US FDA panel backs Replimune skin cancer drug study data
Reuters | 2026-07-30 17:10:52
07/31/2026 07:05 PM ZBAO Zhibao Technology Inc. Class A Ordi 31-Jul 09:20 0.20 0.31 0.14 82.35 0.15 1.34 $0.15 ~ $1.34 Financial Insurance Brokers 374.60 6.54
07/31/2026 07:05 PM LBGJ Li Bang International Corporation I 31-Jul 09:20 0.02 0.03 0.01 50.00 0.02 177.00 $0.02 ~ $177.00 Industrials Specialty Industrial Machinery 910.94 0.00
07/31/2026 07:05 PM AXTI AXT, Inc. 31-Jul 09:20 60.43 67.34 20.40 43.46 1.85 143.16 $1.85 ~ $143.16 Technology Semiconductor Equipment & Materials 29.17 3.07 AXTI Q2 Earnings Beat on Record InP Demand, Revenues Rise Y/Y
Zacks Investment Research | 2026-07-31 12:15:18
AXTI Q2 Earnings Call Highlights AI Capacity Expansion
Zacks Investment Research | 2026-07-31 11:31:19
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
Benzinga | 2026-07-31 10:05:40
AXT, Inc. (AXTI) Q2 2026 Earnings Call Transcript
Seeking Alpha | 2026-07-31 00:23:13
AXT Q2 Earnings Call Highlights
MarketBeat | 2026-07-30 18:06:46
07/31/2026 07:03 PM COHU Cohu, Inc. 31-Jul 09:20 47.99 58.69 12.24 26.35 17.87 74.60 $17.87 ~ $74.60 Technology Semiconductor Equipment & Materials 2.58 2.26 COHU Q2 Earnings Beat Estimates on AI Compute and Favorable Mix
Zacks Investment Research | 2026-07-31 11:41:13
Cohu (COHU) Q2 Earnings and Revenues Surpass Estimates
Zacks Investment Research | 2026-07-30 18:26:06
Cohu Q2 Earnings Call Highlights
MarketBeat | 2026-07-30 18:06:30
07/31/2026 07:05 PM ONFO Onfolio Holdings, Inc. 31-Jul 09:20 0.08 0.10 0.02 25.00 0.06 2.48 $0.06 ~ $2.48 Communication Services Internet Content & Information 295.88 430.00 Onfolio Explores Strategic Alternatives to Sharpen Portfolio
Zacks Investment Research | 2026-07-29 11:41:02
07/31/2026 07:05 PM SBEV Splash Beverage Group, Inc. 31-Jul 09:20 0.37 0.43 0.08 22.86 0.25 13.40 $0.25 ~ $13.40 Consumer Defensive Beverages - Wineries & Distilleries 24.82 270.00

Bio-Pharm Insight

FDA Calendar

Date Symbol Company time event_type Drug Drug Details Status Catalyst target_date_from target_date_to Catalyst Summary Source
07/24/2026 MNKD MannKind Corporation 06:30 AM FDA Decision Furoscix ReadyFlow™ (furosemide injection) Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure (HF) or chronic kidney disease (CKD). FDA Approved FDA Decision 07/24/2026 07/24/2026 MannKind Corporation (MNKD) announced that the U.S. Food and Drug Administration (FDA) has approved Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema, or fluid overload, in adults with heart failure (HF) or chronic kidney disease (CKD).
07/24/2026 OTLK Outlook Therapeutics 02:40 AM FDA Decision YTENAVA™ (bevacizumab-vikg) LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. FDA Approved FDA Decision 07/24/2026 07/24/2026 The U.S. Food and Drug Administration (FDA) has approved Outlook Therapeutics' (OTLK) LYTENAVA™ (bevacizumab-vikg) for the treatment of adults with neovascular age-related macular degeneration (nAMD), commonly known as wet AMD.
07/23/2026 IKT Inhibikase Therapeutics 08:00 AM FDA Decision IKT-001 IKT-001 for Pulmonary Arterial Hypertension (PAH) Orphan Drug Designation FDA Grant 07/23/2026 07/23/2026 Inhibikase Therapeutics (IKT) said the U.S. Food and Drug Administration granted orphan drug designation to its lead drug candidate, IKT-001, for the treatment of pulmonary arterial hypertension (PAH).
07/22/2026 GSK GSK plc 01:59 PM FDA Decision Jideytro (zidesamtinib) Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. FDA Approved FDA Decision 07/22/2026 07/22/2026 GSK plc (GSK) said the FDA approved Jideytro (zidesamtinib) for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received a ROS1 kinase inhibitor. The approval came ahead of the FDA's Sept. 18, 2026 target action date
07/21/2026 OSUR OraSure Technologies 04:30 PM FDA Decision OraQuick™ Ebola 2.0 Rapid Antigen Test The second generation OraQuick™ Ebola 2.0 Rapid Antigen Test for use with whole blood in live patients, as well as cadaveric oral fluid from individuals suspected to have had Ebola disease at the time of death. The test can detect all four Ebola viruses currently known to cause disease in humans: Bundibugyo, Zaire, Sudan, and Taï Forest. Emergency Use Authorization FDA Decision 07/21/2026 07/21/2026 OraSure Technologies (OSUR) received U.S. Food and Drug Administration emergency use authorization for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test. The authorization covers use of the test with whole blood from live patients and cadaveric oral fluid from individuals suspected to have had Ebola disease at the time of death. The point-of-care test is designed to detect all four Ebola virus species known to cause disease in humans: Bundibugyo, Zaire, Sudan and Taï Forest.
07/20/2026 ACAD Acadia Pharmaceuticals 09:05 AM FDA Decision Remlifanserin Remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Fast Track Designation FDA Grant 07/20/2026 07/20/2026 Acadia Pharmaceuticals (ACAD) said the U.S. Food and Drug Administration granted Fast Track designation to its investigational drug Remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.
07/20/2026 ONCY Oncolytics Biotech 09:00 AM FDA Decision Pelareorep Pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on or were intolerant to one or more prior lines of systemic therapy. Fast Track Designation FDA Grant 07/20/2026 07/20/2026 Oncolytics Biotech (ONCY) announced that the FDA granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for treating patients with advanced squamous cell carcinoma of the anal canal (SCAC).

After Hour Movers

Date Time Symbol Company Name Last Updated Close Price Change Percent Day Range 52Wk Range Sector / Industry dailyvolume marketcap news_link Catalyst News
07/31/2026 07:05 PM UPC Universe Pharmaceuticals Inc. 31-Jul 19:05 3.16 6.27 3.11 98.42 $3.16 ~ $3.48 $2.00 ~ $17.96 14.53 2.00
07/31/2026 07:05 PM FCUV Focus Universal Inc. 31-Jul 19:05 11.60 17.96 6.36 54.83 $8.42 ~ $17.59 $1.79 ~ $210.00 93.37 2.34
07/31/2026 07:05 PM FNGR FingerMotion, Inc. 31-Jul 19:05 0.27 0.39 0.12 44.44 $0.23 ~ $0.27 $0.23 ~ $2.20 908.22 16.55
07/31/2026 07:05 PM VIVK Vivakor, Inc. 31-Jul 19:05 1.94 2.22 0.28 14.43 $1.88 ~ $2.28 $1.45 ~ $4,951.64 4.10 690.00
07/31/2026 07:01 PM HSCS HeartSciences Inc. 31-Jul 19:01 2.04 2.33 0.29 14.22 $1.98 ~ $2.07 $1.63 ~ $3.93 27.11 4.41
07/31/2026 06:47 PM BAOS Baosheng Media Group Holdings Limit 31-Jul 18:47 0.57 0.64 0.07 12.28 $0.57 ~ $0.60 $0.50 ~ $5.40 71.74 880.00
07/31/2026 07:03 PM XAIR Beyond Air, Inc. 31-Jul 19:03 5.28 5.92 0.64 12.12 $5.02 ~ $5.42 $5.02 ~ $95.60 27.91 3.80
07/31/2026 07:05 PM SGLY Singularity Future Technology Ltd. 31-Jul 19:05 5.23 5.86 0.63 12.05 $4.40 ~ $5.47 $2.52 ~ $20.30 28.21 1.45
07/31/2026 03:55 PM SBDS Solo Brands, Inc. 31-Jul 15:55 3.42 3.82 0.40 11.70 $3.42 ~ $3.42 $3.04 ~ $20.93 0.19 8.75
07/31/2026 05:20 PM SCKT Socket Mobile, Inc. 31-Jul 17:20 0.40 0.44 0.04 10.00 $0.40 ~ $0.46 $0.40 ~ $1.36 97.63 3.30 Socket Mobile, Inc. (SCKT) Q2 2026 Earnings Call Transcript
Seeking Alpha | 2026-07-30 18:53:32

After Hour Insights

© CatalystPICR 2025-26